Organon and Claria Medical have reached an agreement to promote the latter’s medical device, which works and improves on the minimally invasive laparoscopic hysterectomy. The agreement also grants Organon the option to acquire Claria Medical.
Hysterectomy is one of the most commonly performed surgeries in womenso it is essential to invest in new technologies with the aim of providing safer, simpler and faster procedures», has assured Kevin Ali, CEO of Organon. «Collaborations like our agreement with Claria Medical are an integral part of our approach to business development. We look for possible solutions to improve women’s health wherever they are available, whether they are drugs, devices or other technologies. This agreement builds on our device expertise and aligns with our focus on advancing urgently needed innovations.”
Claria’s initial research device, the “Claria System”, uses an intelligent uterine containment and extraction system which aims to improve the hysterectomy procedure for both patients and physicians. The device was selected for inclusion in the US Food and Drug Administration’s (FDA) Safer Technologies Program (STeP), a collaborative program that seeks to reduce the time the time it takes to obtain marketing authorization for eligible devices.
Alexey Salamini, CEO of Claria Medical, commented: “Our team is excited about this strategic agreement with Organon, as it brings extensive knowledge about women’s health. Organon’s investment reinforces the potential of our technology to help improve outcomes for women. We are very much looking forward to continuing our clinical program for the Claria System and obtaining FDA clearance.”
Under the terms of the agreement, Organon will perform an initial payment of 8 million dollars and you will have the option to purchase Claria Medical on pre-defined terms. The advance payment will be classified as a 2023 research and development expense.
